Precision. Validation. Innovation.

Accelerating Molecular Velocity through Advanced Analytics.

We are an FDA-registered analytical testing laboratory specializing in the rigorous kinetic evaluation and quality control of pharmaceutical compounds, from API synthesis to final drug product validation.

Our Mission

TLI Therapeutics is the industry-leading pharmaceutical and diagnostics company that aims to establish positions in large and rapidly growing medical markets by leveraging our discovery, development, and commercialization expertise and our novel and proprietary technologies. We intend to leverage our global commercialization expertise to pursue acquisitions of commercial businesses that will both drive our growth and provide geographically diverse sales and distribution opportunities.







Rigorous Analytical Vectors

Our validated methodologies cover the full lifecycle of drug development, ensuring compliance, purity, and efficacy at every stage.

Method Development & Validation

Establishing and validating novel analytical procedures (USP/ICH/FDA compliant) for complex matrices and trace impurity analysis, ensuring robust and reproducible data generation.

View Validation Matrix

Stability & Degradation Studies

Executing accelerated and long-term stability protocols (ICH Q1A-Q1F) to define shelf-life, characterize degradation pathways, and quantify related substances with high fidelity.

Define Stress Protocols

Manufacturing QC & Release

Providing critical quality control testing (finished product release, raw material analysis, excipient verification) under stringent GMP guidelines to ensure batch conformity.

Explore QC Framework
Our Analytical Paradigm

The TLI Kinetic Assurance Pipeline.

We integrate state-of-the-art instrumentation with highly credentialed Ph.D. chemists to provide data integrity that withstands the most rigorous regulatory scrutiny. Our four-phase process guarantees scientific precision.

  • Full spectroscopic and chromatographic capabilities
  • Dedicated dissolution and bioavailability modeling
  • GxP compliant data archiving and reporting
Download Technical Specifications
01

Protocol Initiation

Define scope, required LOD/LOQ, and regulatory pathway alignment (FDA/EMA).

02

Analytical Execution

Chromatographic separation, quantitative mass spectrometry, and validation runs.

03

Data Integrity & Review

Internal QA/QC audits, statistical process control, and raw data verification.

04

Certificated Release

Final CoA (Certificate of Analysis) delivery and comprehensive report generation.

Regulatory Conformance

FDA Registration and Full GxP Compliance since 2012.

Uncompromising Data Sovereignty

Regulatory compliance is the bedrock of our operation. Our facilities, SOPs, and reporting structures are meticulously maintained to exceed FDA guidelines, minimizing risk in your development lifecycle.

21 CFR Part 11 Compliant

Secure electronic records and verifiable audit trails.

cGMP Framework

Quality systems supporting clinical and commercial release batches.

Initial Project Intake

Initiate Kinetic Analysis.

Connect with our Principal Scientists to discuss your specific analytical challenges, timeline requirements, and project scope definition.

New Business Inquiries:

info@TLITherapeutics.com

Direct Line:

(919) 746-8024

Research Facility Location

TLI Therapeutics, LLC

One Park Drive

Research Triangle Park

North Carolina 27709, USA

Ph: 1 (919) 746-8024

European Operations

TLI Therapeutics, LLC

1 Portland Street

Manchester M1 3BE

United Kingdom

Ph: 44 (0) 161 394 1553